Some companies with mRNA manufacturing capacity
Alnylam Pharmaceutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
BeiGene
BioNtech SE
CurVac NV
Dicerna Pharmaceuticals
Genmab
Gritstone Bio.
Lonza
Maravai LifeSciences Holdings
Marian Biotech
Moderna
mRNA RiboTherapeutics, Inc.
Pfizer
Sanofi
Sorrento Therapeutics
Tekmira Pharmaceuticals Corporation
Translate Bio
Vertex
Some random SEC filings.
Sorrento Therapeutics
https://www.sec.gov/Archives/edgar/data/850261/000110465921102102/tm2124587d1_ex99-1.htm
mRNA RiboTherapeutics, Inc., Second Amendment to Patent Sublicense Agreement
https://www.sec.gov/Archives/edgar/data/1776985/000156459021016723/bntx-ex422_413.htm
Tekmira Pharmaceuticals Corporation
https://www.sec.gov/Archives/edgar/data/1447028/000117184313004142/newsrelease.htm
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
https://www.sec.gov/Archives/edgar/data/1768224/000119380521001134/e620853_ex99-1.htm
Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases
https://www.sec.gov/Archives/edgar/data/1693415/000119312518214210/d709987dex991.htm
CureVac Streamlines European Network for mRNA Product Manufacturing
https://www.sec.gov/Archives/edgar/data/1809122/000110465921115517/tm2127628d1_ex99-1.htm
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
https://www.sec.gov/Archives/edgar/data/1693415/000119312521234062/d191890dex993.htm
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
https://www.sec.gov/Archives/edgar/data/1434265/000155837019011603/ex-99d1.htm
Marina Biotech
https://www.sec.gov/Archives/edgar/data/737207/000119312512035642/d293191dex991.htm
Novartis. CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV
https://www.sec.gov/Archives/edgar/data/1809122/000110465921031844/tm218659d1_ex99-1.htm
Arcturus Therapeutics, Inc.
https://www.sec.gov/Archives/edgar/data/0001566049/000156459018013460/arct-ex413_1676.htm
Lonza.
https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/lonzamodernagltafullye.htm
mRNA RiboTherapeutics, Inc. This Patent Sublicense Agreement (“Agreement”) is between mRNA RiboTherapeutics, Inc., a Wisconsin corporation having a place of business at 726 Post Road, Madison, WI 53713, USA (“mRNA RiboTherapeutics”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date“). Each of Company and mRNA RiboTherapeutics are referred to herein as a “Party” and collectively as the “Parties”.
https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1016.htm
Research Collaboration and License Agreement by and between Pfizer inc. and BioNTech RNA Pharmaceuticals gmbh and Biontech AG
https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1018.htm
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals, February 22, 2021
https://www.sec.gov/Archives/edgar/data/1768224/000119380521000256/e620313_ex99-1.htm
Curevac AG and Genmab B.V. license.
https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex10-1.htm
Arcturus Therapeutics 2018 10-K.
https://www.sec.gov/Archives/edgar/data/0001566049/000156459019008092/arct-10k_20181231.htm
Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc. dated 1 January 2018.
https://www.sec.gov/Archives/edgar/data/1566049/000156459018013460/arct-ex412_1677.htm
Misc company web pages:
Aldevron. https://www.aldevron.com/platforms/mrna-production